← Back to Screener
Sanara MedTech Inc. Common Stock (SMTI)
Price$19.78
Favorite Metrics
Price vs S&P 500 (26W)-42.08%
Price vs S&P 500 (4W)1.41%
Market Capitalization$183.43M
All Metrics
P/CF (Annual)27.03x
Book Value / Share (Quarterly)$0.66
P/TBV (Annual)36.61x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)31.03%
Cash Flow / Share (Quarterly)$0.24
Price vs S&P 500 (YTD)-16.95%
Gross Margin (TTM)92.78%
Net Profit Margin (TTM)-45.98%
EPS (TTM)$-4.35
10-Day Avg Trading Volume0.04M
EPS Excl Extra (TTM)$-4.35
Revenue Growth (5Y)45.91%
EPS (Annual)$-4.36
ROI (Annual)-72.36%
Gross Margin (Annual)92.71%
Net Profit Margin (5Y Avg)-20.87%
Cash / Share (Quarterly)$1.85
Revenue Growth QoQ (YoY)4.72%
ROA (Last FY)-51.50%
Revenue Growth TTM (YoY)-10.80%
EBITD / Share (TTM)$0.63
ROE (5Y Avg)-142.30%
Operating Margin (TTM)2.47%
Cash Flow / Share (Annual)$0.24
P/B Ratio30.89x
P/B Ratio (Quarterly)35.14x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)2.75x
Net Interest Coverage (TTM)0.95x
ROA (TTM)-44.30%
EV / EBITDA (TTM)39.35x
EPS Incl Extra (Annual)$-4.36
Current Ratio (Annual)1.80x
Quick Ratio (Quarterly)1.54x
3-Month Avg Trading Volume0.06M
52-Week Price Return-33.21%
EV / Free Cash Flow (Annual)99.57x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$1.30
P/S Ratio (Annual)1.78x
Asset Turnover (Annual)1.41x
52-Week High$35.95
Operating Margin (5Y Avg)-11.50%
EPS Excl Extra (Annual)$-4.36
CapEx CAGR (5Y)23.17%
26-Week Price Return-38.10%
Quick Ratio (Annual)1.54x
13-Week Price Return-16.50%
Total Debt / Equity (Annual)7.74x
Current Ratio (Quarterly)1.80x
Enterprise Value$212.825
Revenue / Share Growth (5Y)34.46%
Asset Turnover (TTM)0.96x
Book Value / Share Growth (5Y)-7.43%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)2.24x
Pretax Margin (Annual)-0.38%
Cash / Share (Annual)$1.85
3-Month Return Std Dev58.17%
Gross Margin (5Y Avg)89.56%
Net Income / Employee (TTM)$-0
ROE (Last FY)-632.53%
Net Interest Coverage (Annual)0.25x
EPS Basic Excl Extra (Annual)$-4.36
P/FCF (TTM)31.31x
Receivables Turnover (TTM)6.32x
EV / Free Cash Flow (TTM)99.57x
Total Debt / Equity (Quarterly)7.74x
EPS Incl Extra (TTM)$-4.35
Receivables Turnover (Annual)8.44x
ROI (TTM)-57.16%
P/S Ratio (TTM)2.37x
Pretax Margin (5Y Avg)-14.59%
Revenue / Share (Annual)$11.96
Tangible BV / Share (Annual)$1.24
Forward P/E172.09x
Price vs S&P 500 (52W)-63.04%
Year-to-Date Return-14.30%
5-Day Price Return17.91%
EPS Normalized (Annual)$-4.36
ROA (5Y Avg)-20.61%
Net Profit Margin (Annual)-36.43%
Month-to-Date Return16.47%
Cash Flow / Share (TTM)$-0.60
EBITD / Share (Annual)$1.16
Operating Margin (Annual)7.08%
LT Debt / Equity (Annual)7.74x
P/CF (TTM)27.03x
ROI (5Y Avg)-27.77%
LT Debt / Equity (Quarterly)7.74x
EPS Basic Excl Extra (TTM)$-4.35
P/TBV (Quarterly)30.53x
P/B Ratio (Annual)35.14x
Inventory Turnover (TTM)2.24x
Pretax Margin (TTM)-4.92%
Book Value / Share (Annual)$0.66
Price vs S&P 500 (13W)-17.19%
Beta1.21x
P/FCF (Annual)85.82x
Revenue / Share (TTM)$8.93
ROE (TTM)-178.53%
52-Week Low$16.05
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.13
4.13
4.13
4.14
Industry Peers — Orthopedic & Prosthetic Devices(25)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
SMTISanara MedTech Inc. Common Stock | 2.37x | 45.91% | 92.78% | 2.47% | $19.78 |
ISRGIntuitive Surgical Inc. | 16.35x | 18.22% | 66.00% | 29.27% | $458.08 |
EWEdwards Lifesciences Corp | 7.42x | 6.70% | 78.01% | 18.41% | $79.05 |
STESTERIS plc | 3.70x | 12.49% | 44.11% | 17.03% | $219.97 |
ZBHZimmer Biomet Holdings, Inc. | 2.28x | 3.22% | 69.71% | 13.34% | $94.78 |
ALGNAlign Technology Inc | 3.29x | 10.30% | 68.27% | 13.53% | $185.02 |
SNNSmith & Nephew plc | 2.36x | 6.21% | 68.01% | 12.88% | $33.83 |
MSAMine Safety Incorporated | 3.40x | 6.82% | 46.46% | 19.83% | $165.17 |
ESTAEstablishment Labs Holdings Inc. | 8.96x | 20.04% | 69.32% | -18.48% | $64.51 |
ENOVEnovis Corporation | 0.65x | -6.05% | 58.16% | -50.09% | $25.20 |
CDRECadre Holdings, Inc. | 2.32x | 8.57% | 42.54% | 11.04% | $30.43 |
About
Sanara MedTech develops medical technologies for wound and skincare management across acute and post-acute care settings. Its portfolio includes CellerateRX for surgical wounds and BIAKOS for chronic wound care, addressing a substantial market opportunity. The company's comprehensive product offerings target improved clinical outcomes and reduced healthcare costs.